TY - JOUR
T1 - CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment
AU - Bao, Shunshun
AU - Darvishi, Mohammad
AU - H Amin, Ali
AU - Al-Haideri, Maysoon T.
AU - Patra, Indrajit
AU - Kashikova, Khadisha
AU - Ahmad, Irfan
AU - Alsaikhan, Fahad
AU - Al-qaim, Zahraa Haleem
AU - Al-Gazally, Moaed E.
AU - Kiasari, Bahman Abedi
AU - Tavakoli-Far, Bahareh
AU - Sidikov, Akmal A.
AU - Mustafa, Yasser Fakri
AU - Akhavan-Sigari, Reza
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023/8
Y1 - 2023/8
N2 - CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.
AB - CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.
KW - CXCL12/CXCR4 axis
KW - CXCR4
KW - CXCR4 blockers
KW - Cancer
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85149776759&partnerID=8YFLogxK
U2 - 10.1007/s00432-022-04444-w
DO - 10.1007/s00432-022-04444-w
M3 - Review article
C2 - 36905421
AN - SCOPUS:85149776759
SN - 0171-5216
VL - 149
SP - 7945
EP - 7968
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 10
ER -
